Skip to main content
SpringerLink
Log in

Replacing the NCCN’s Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice?

  • Commentary
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 26 June 2020

A Letter to the Editor to this article was published on 26 June 2020

The Original Article was published on 23 March 2020

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Mitchell AP, Dey P, Ohn JA, Tabatabai SM, Curry MA, Bach PB. The accuracy and usefulness of the National Comprehensive Cancer Network Evidence Blocks affordability rating. Pharmacoeconomics. 2020;78:89. https://doi.org/10.1007/s40273-020-00901-x(Accessed 9 Apr 2020).

    Article  Google Scholar 

  2. Levinsky NG. The doctor’s master. N Engl J Med. 1984;311(24):1573–5.

    Article  CAS  Google Scholar 

  3. Pollack A. Cost of treatment may influence doctors. The New York Times. 2014. https://www.nytimes.com/2014/04/18/business/treatment-cost-could-influence-doctors-advice.html. Accessed 27 Mar 2020].

  4. Espay AJ, Norris MM, Eliassen JC, et al. Placebo effect of medication cost in Parkinson disease: a randomized double-blind study. Neurology. 2015;84(8):794–802.

    Article  Google Scholar 

  5. Waber RL, Shiv B, Carmon Z, Ariely D. Commercial features of placebo and therapeutic efficacy. JAMA. 2008;299(9):1016–7.

    Article  CAS  Google Scholar 

  6. Cohen JT, Lin PJ, Sheinson DM, et al. Are National Comprehensive Cancer Network Evidence Block affordability ratings representative of real-world costs? An evaluation of advanced non-small-cell lung cancer. J Oncol Pract. 2019;15(11):e948–56.

    Article  Google Scholar 

  7. Prasad V, De Jesús K, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol. 2017;14(6):381–90.

    Article  Google Scholar 

  8. Mailankody S, Prasad V. Five years of cancer drug approvals: innovation, efficacy, and costs. JAMA Oncol. 2015;1(4):539–40.

    Article  Google Scholar 

  9. Prasad V, Mailankody S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med. 2017;177(11):1569–75.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oregon Health and Science University School of Medicine, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA

    Audrey A. Tran & Vinay Prasad

  2. Division of Hematology Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA

    Audrey A. Tran & Vinay Prasad

  3. Department of Public Health and Preventive Medicine, Oregon Health and Science University, Portland, OR, USA

    Vinay Prasad

Authors
  1. Audrey A. Tran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vinay Prasad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vinay Prasad.

Ethics declarations

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Conflict of interest

Vinay Prasad has received research funding from Arnold Ventures, royalties from Johns Hopkins Press, honoraria from Medscape, grand rounds/lectures in universities, medical centers, non-profit organizations, and professional societies, consulting fees from UnitedHealthcare, speaking fees from Evicore, and has a Plenary Session podcast backed by Patreon. Audrey A. Tran has no conflicts of interest that are directly relevant to the content of this commentary.

Additional information

This paper comments on https://link.springer.com/article/10.1007/s40273-020-00901-x.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tran, A.A., Prasad, V. Replacing the NCCN’s Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice?. PharmacoEconomics 38, 729–731 (2020). https://doi.org/10.1007/s40273-020-00920-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40273-020-00920-8

Search

Navigation